Cover Image
市場調查報告書

Opexa Therapeutics, Inc. 的產品平台分析

Opexa Therapeutics, Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 321993
出版日期 內容資訊 英文 24 Pages
訂單完成後即時交付
價格
Back to Top
Opexa Therapeutics, Inc. 的產品平台分析 Opexa Therapeutics, Inc. - Product Pipeline Review - 2015
出版日期: 2015年08月31日 內容資訊: 英文 24 Pages
簡介

Opexa Therapeutics, Inc. 是總公司設立於美國的生物科技企業,正在開發治療硬化症和類風濕性關節炎,糖尿病,心臟衰竭等疾病的自我細胞醫藥品。並已開發出生產單核幹細胞所用的技術。

本報告提供Opexa Therapeutics, Inc. 的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Opexa Therapeutics, Inc. 的基本資料

  • Opexa Therapeutics, Inc. 概要
  • 主要資訊
  • 企業資料

Opexa Therapeutics, Inc. :R&D概要

  • 主要的治療範圍

Opexa Therapeutics, Inc. :開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Opexa Therapeutics, Inc. :開發中產品概況

  • 臨床階段的開發中產品
    • 第二階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

Opexa Therapeutics, Inc. :藥物簡介

  • imilecleucel-t
  • OPX-212
  • Stem Cell Therapy for Type 1 Diabetes

Opexa Therapeutics, Inc. :開發平台分析

  • 各給藥途徑
  • 各分子類型

Opexa Therapeutics, Inc. :最新的開發平台資訊

Opexa Therapeutics, Inc. :總公司和子公司的所在地

  • 總公司
  • 分公司及子公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07544CDB

Summary

Global Markets Direct's, 'Opexa Therapeutics, Inc. - Product Pipeline Review - 2015', provides an overview of the Opexa Therapeutics, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Opexa Therapeutics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Opexa Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Opexa Therapeutics, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Opexa Therapeutics, Inc.'s pipeline products

Reasons to buy

  • Evaluate Opexa Therapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Opexa Therapeutics, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Opexa Therapeutics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Opexa Therapeutics, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Opexa Therapeutics, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Opexa Therapeutics, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Opexa Therapeutics, Inc. Snapshot
    • Opexa Therapeutics, Inc. Overview
    • Key Information
    • Key Facts
  • Opexa Therapeutics, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Opexa Therapeutics, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Opexa Therapeutics, Inc. - Pipeline Products Glance
    • Opexa Therapeutics, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Opexa Therapeutics, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Opexa Therapeutics, Inc. - Drug Profiles
    • imilecleucel-t
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • OPX-212
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Stem Cell Therapy for Type 1 Diabetes
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Opexa Therapeutics, Inc. - Pipeline Analysis
    • Opexa Therapeutics, Inc. - Pipeline Products by Target
    • Opexa Therapeutics, Inc. - Pipeline Products by Route of Administration
    • Opexa Therapeutics, Inc. - Pipeline Products by Molecule Type
    • Opexa Therapeutics, Inc. - Pipeline Products by Mechanism of Action
  • Opexa Therapeutics, Inc. - Recent Pipeline Updates
  • Opexa Therapeutics, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Opexa Therapeutics, Inc., Key Information
  • Opexa Therapeutics, Inc., Key Facts
  • Opexa Therapeutics, Inc. - Pipeline by Indication, 2015
  • Opexa Therapeutics, Inc. - Pipeline by Stage of Development, 2015
  • Opexa Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015
  • Opexa Therapeutics, Inc. - Phase II, 2015
  • Opexa Therapeutics, Inc. - Preclinical, 2015
  • Opexa Therapeutics, Inc. - Pipeline by Target, 2015
  • Opexa Therapeutics, Inc. - Pipeline by Route of Administration, 2015
  • Opexa Therapeutics, Inc. - Pipeline by Molecule Type, 2015
  • Opexa Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2015
  • Opexa Therapeutics, Inc. - Recent Pipeline Updates, 2015

List of Figures

  • Opexa Therapeutics, Inc. - Pipeline by Top 10 Indication, 2015
  • Opexa Therapeutics, Inc. - Pipeline by Stage of Development, 2015
  • Opexa Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015
  • Opexa Therapeutics, Inc. - Pipeline by Top 10 Route of Administration, 2015
  • Opexa Therapeutics, Inc. - Pipeline by Top 10 Molecule Type, 2015
Back to Top